ROCKVILLE, Md., Oct. 30,
2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:
RGNX) today announced presentations at the American Academy of
Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, 2023 in San Francisco, CA. The presentations will
highlight new data for ABBV-RGX-314, an investigational one-time
AAV Therapeutic being developed in collaboration with AbbVie for
the treatment of wet age-related macular degeneration (wet AMD),
diabetic retinopathy (DR) and other additional chronic retinal
conditions.
Title: ALTITUDE®: Suprachoroidal Delivery of
ABBV-RGX-314 investigational Gene Therapy for Diabetic Retinopathy;
Dose Level 1 and 2: 1-Year Results
Presenter: Mark Barakat,
M.D., Retinal Consultants of Arizona
Section VIII: Late breaking Developments, Part I
Date/Time: Friday, November 3,
2023, 3:53 – 3:58 p.m. PT
This data will also be presented by Arshad Khanani M.D., M.A., FASRS, Director of
Clinical Research at Sierra Eye Associates, Reno, NV on Sunday,
November 5, 2023, 4:09 – 4:16 p.m.
PT.
REGENXBIO will host a conference call Monday, November 6, 2023 at 8:30 a.m. EST with Dr. Barakat and Dr.
Peter Kaiser, Chaney Family Endowed
Chair in Ophthalmology Research and Professor of Ophthalmology,
Cleveland Clinic Lerner College of Medicine and Cole Eye Institute,
to discuss these results and the ABBV-RGX-314 program.
Conference call details
Listeners can register for the
webcast via this link. Analysts wishing to participate in the
question and answer session should use this link. A copy of the
slides being presented will be available via the Company's investor
website. Those who plan on participating are advised to join 15
minutes prior to the start time. A replay of the webcast will also
be available via the Company's investor website approximately two
hours after the call's conclusion.
About REGENXBIO Inc.
REGENXBIO is a leading
clinical-stage biotechnology company seeking to improve lives
through the curative potential of gene therapy. REGENXBIO's NAV
Technology Platform, a proprietary adeno-associated virus (AAV)
gene delivery platform, consists of exclusive rights to more than
100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and
its third-party NAV Technology Platform Licensees are applying the
NAV Technology Platform in the development of a broad pipeline of
candidates, including late-stage and commercial programs, in
multiple therapeutic areas. REGENXBIO is committed to a "5x'25"
strategy to progress five AAV Therapeutics from our internal
pipeline and licensed programs into pivotal-stage or commercial
products by 2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2023-annual-meeting-301971001.html
SOURCE REGENXBIO Inc.